$942 Million is the total value of Casdin Capital, LLC's 38 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 31.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $90,644,000 | +20.4% | 1,550,000 | +64.9% | 9.62% | +38.9% |
| SRPT | SAREPTA THERAPEUTICS INC | $65,539,000 | -24.2% | 670,000 | 0.0% | 6.96% | -12.5% | |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $63,677,000 | +7.4% | 585,000 | +13.6% | 6.76% | +23.9% |
| FATE | FATE THERAPEUTICS INC | $56,636,000 | +13.5% | 2,550,000 | 0.0% | 6.01% | +31.0% | |
| CDXS | CODEXIS INC | $56,623,000 | -30.2% | 5,073,780 | 0.0% | 6.01% | -19.4% | |
| BLUE | Buy | BLUEBIRD BIO INC | $50,786,000 | -40.3% | 1,105,000 | +13.9% | 5.39% | -31.1% |
| NVTA | Sell | INVITAE CORP | $47,550,000 | -19.0% | 3,478,388 | -4.4% | 5.05% | -6.5% |
| MYOK | Sell | MYOKARDIA INC | $46,646,000 | -36.3% | 995,000 | -1.0% | 4.95% | -26.5% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $37,964,000 | -3.6% | 1,070,000 | +29.7% | 4.03% | +11.2% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $30,801,000 | -46.1% | 980,000 | -19.2% | 3.27% | -37.8% |
| TWST | Buy | TWIST BIOSCIENCE CORP | $30,580,000 | +385.4% | 1,000,000 | +233.3% | 3.25% | +460.6% |
| RVMD | New | REVOLUTION MEDICINES INC | $28,911,000 | – | 1,319,536 | +100.0% | 3.07% | – |
| CDNA | Buy | CAREDX INC | $28,255,000 | +9.2% | 1,294,335 | +7.9% | 3.00% | +26.0% |
| ALEC | ALECTOR INC | $25,965,000 | +40.0% | 1,076,039 | 0.0% | 2.76% | +61.6% | |
| DNLI | Buy | DENALI THERAPEUTICS INC | $25,477,000 | +17.0% | 1,455,000 | +16.4% | 2.70% | +35.1% |
| BLFS | BIOLIFE SOLUTIONS INC | $23,451,000 | -41.3% | 2,468,571 | 0.0% | 2.49% | -32.2% | |
| ADPT | Buy | ADAPTIVE BIOTECHNOLOGIES COR | $22,033,000 | +59.0% | 793,125 | +71.3% | 2.34% | +83.6% |
| MGTA | Sell | MAGENTA THERAPEUTICS INC | $18,658,000 | -60.3% | 2,971,034 | -4.1% | 1.98% | -54.1% |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $15,327,000 | -35.7% | 300,000 | 0.0% | 1.63% | -25.8% | |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $14,439,000 | -30.0% | 1,209,285 | -2.4% | 1.53% | -19.1% |
| GNMK | GENMARK DIAGNOSTICS INC | $13,864,000 | -14.3% | 3,365,000 | 0.0% | 1.47% | -1.1% | |
| GRTS | Buy | GRITSTONE ONCOLOGY INC | $13,211,000 | -31.8% | 2,270,000 | +5.1% | 1.40% | -21.3% |
| GILD | New | GILEAD SCIENCES INC | $13,083,000 | – | 175,000 | +100.0% | 1.39% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $11,299,000 | – | 266,430 | +100.0% | 1.20% | – |
| SAGE | Buy | SAGE THERAPEUTICS INC | $11,057,000 | -33.4% | 385,000 | +67.4% | 1.17% | -23.1% |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $10,991,000 | – | 1,125,000 | +100.0% | 1.17% | – |
| VYGR | VOYAGER THERAPEUTICS INC | $10,020,000 | -34.4% | 1,095,075 | 0.0% | 1.06% | -24.3% | |
| ZLAB | New | ZAI LAB LTDadr | $9,781,000 | – | 190,000 | +100.0% | 1.04% | – |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $9,720,000 | – | 500,000 | +100.0% | 1.03% | – |
| BMYRT | Buy | BRISTOL-MYERS SQUIBB COright | $9,500,000 | +110.4% | 2,500,000 | +66.7% | 1.01% | +142.9% |
| SGMO | SANGAMO THERAPEUTICS INC | $9,268,000 | -23.9% | 1,455,000 | 0.0% | 0.98% | -12.1% | |
| ILMN | Sell | ILLUMINA INC | $8,194,000 | -58.8% | 30,000 | -50.0% | 0.87% | -52.5% |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $7,342,000 | -34.9% | 975,000 | +18.9% | 0.78% | -24.9% |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $7,220,000 | – | 289,395 | +100.0% | 0.77% | – |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $5,764,000 | -63.7% | 140,000 | -45.1% | 0.61% | -58.1% |
| New | DERMTECH INC | $5,642,000 | – | 571,713 | +100.0% | 0.60% | – | |
| TPTX | TURNING POINT THERAPEUTICS I | $3,350,000 | -28.3% | 75,000 | 0.0% | 0.36% | -17.2% | |
| STOK | Sell | STOKE THERAPEUTICS INC | $2,748,000 | -25.4% | 120,000 | -7.7% | 0.29% | -13.9% |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -200,000 | -100.0% | -1.20% | – |
| BOLD | Exit | AUDENTES THERAPEUTICS INC | $0 | – | -860,000 | -100.0% | -4.73% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.